<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04248868</url>
  </required_header>
  <id_info>
    <org_study_id>THRO-CLIN-2019-01</org_study_id>
    <nct_id>NCT04248868</nct_id>
  </id_info>
  <brief_title>tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden</brief_title>
  <acronym>RESCUE</acronym>
  <official_title>Recombinant tPA by Endovascular Administration for the Treatment of Submassive Pulmonary Embolism Using Pharmaco-mechanical Catheter Directed Thrombolysis for the redUction of Thrombus burdEn</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thrombolex, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Thrombolex, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the efficacy and safety of the Bashir™ Endovascular Catheter for the&#xD;
      administration of pharmaco-mechanical catheter directed therapy using low dose r-tPA for the&#xD;
      treatment of acute submassive pulmonary embolism.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Bashir™ Endovascular Catheter has been designed to administer therapeutic agents in the&#xD;
      peripheral vasculature. Because of the unique design of the catheter, with its six expandable&#xD;
      infusion limbs, the Bashir™ Endovascular Catheter has the ability to: 1. Create a much larger&#xD;
      central channel for blood flow, thereby utilizing the body's own endogenous fibrinolytic&#xD;
      agents to lyse the clot, and 2. Greatly enhance the radial dispersion of a&#xD;
      catheter-administered thrombolytic agent throughout the thrombus. Expansion of the multiple&#xD;
      arms of the basket in the infusion catheter causes fissuring of the clot. The net result is&#xD;
      that a greater surface area of clot is exposed to both endogenous and exogenously&#xD;
      administered lytic agents, thereby promoting clot dissolution.&#xD;
&#xD;
      This study will utilize the Bashir™ Endovascular Catheter and the Bashir Endovascular&#xD;
      Catheter with a short basket (BASHIR™ S-B endovascular catheter) to administer catheter&#xD;
      directed thrombolysis in patients with submassive PE who have consented and meet all&#xD;
      eligibility criteria. The Bashir™ and BASHIR™ S-B endovascular catheters represent a new&#xD;
      methodology for localized catheter-based delivery of thrombolytics. The thrombolytic to be&#xD;
      used in this study is r-tPA (Genentech Corporation, South San Francisco, USA).&#xD;
&#xD;
      The design of the Bashir Endovascular Catheter with the multiple infusion limbs creating a&#xD;
      basket-like formation when expanded, provides an immediate channel for blood flow through the&#xD;
      thrombus and a greater surface area in the thrombus for the endogenous and exogenous&#xD;
      thrombolytics to take effect, as described above.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 23, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Pulse Spray and Infusion of r-tPA</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: RV/LV Ratio Difference</measure>
    <time_frame>48 hours after the completion of r-tPA treatment</time_frame>
    <description>Observe RV/LV diameter ratio difference between baseline and 48 hours after the completion of r-tPA treatment as measured by contrast enhanced chest CT (CTA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Major Bleeding</measure>
    <time_frame>Within 72 hours of initiation of r-tPA administration</time_frame>
    <description>Major Bleeding as defined by International Society of Thrombosis and Hemostasis (ISTH), within 72 hours of initiation of r-tPA administration. Bleeding criteria are as follows: Major Bleeding in Non-Surgical Patients&#xD;
Fatal bleeding; and/or&#xD;
Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome; and/or&#xD;
Bleeding causing a fall in hemoglobin level of 2 g/dL (1.24 mmol/L) or more or leading to transfusion of two or more units of whole blood or red cells.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>BEC Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The Bashir™ Endovascular Catheter</intervention_name>
    <description>The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature.</description>
    <arm_group_label>BEC Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>r-tPA</intervention_name>
    <description>Pulse spray and infusion</description>
    <arm_group_label>BEC Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing and able to provide informed consent;&#xD;
&#xD;
          2. Age 18 to ≤ 75 years of age;&#xD;
&#xD;
          3. PE symptom duration ≤ 14 days.&#xD;
&#xD;
          4. Filling defect in at least one main or lobar pulmonary artery as determined by&#xD;
             contrast enhanced chest CT (CTA);&#xD;
&#xD;
          5. RV/LV diameter ratio ≥ 0.9 by CTA as determined by the investigative site;&#xD;
&#xD;
          6. Willing and able to comply with all study procedures and follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. CVA or TIA within one (1) year;&#xD;
&#xD;
          2. Head trauma, active intracranial, or intraspinal disease ≤ one (1) year prior to&#xD;
             inclusion in the study;&#xD;
&#xD;
          3. Active bleeding from a major organ within one (1) month prior to inclusion in the&#xD;
             study;&#xD;
&#xD;
          4. Intracranial condition(s) that may increase the risk of bleeding (e.g., neoplasms,&#xD;
             arteriovenous malformations, or aneurysms);&#xD;
&#xD;
          5. Patients with bleeding diatheses;&#xD;
&#xD;
          6. Hematocrit &lt; 30%;&#xD;
&#xD;
          7. Platelets &lt; 100,000/μL;&#xD;
&#xD;
          8. INR &gt; 1.5 if currently on warfarin (Coumadin®);&#xD;
&#xD;
          9. aPTT &gt; 50 seconds in the absence of anticoagulants;&#xD;
&#xD;
         10. Major surgery ≤ 14 days prior to inclusion in the study;&#xD;
&#xD;
         11. Serum creatinine &gt; 2.0mg/dL;&#xD;
&#xD;
         12. Clinician deems high-risk for catastrophic bleeding;&#xD;
&#xD;
         13. History of heparin-induced thrombocytopenia (HIT Syndrome);&#xD;
&#xD;
         14. Pregnancy;&#xD;
&#xD;
         15. SBP &lt; 90 mmHg &gt; 15 minutes within two (2) hours prior to BEC procedure and is not&#xD;
             resolved with IV fluids;&#xD;
&#xD;
         16. Any vasopressor support;&#xD;
&#xD;
         17. Cardiac arrest (including pulseless electrical activity and asystole) requiring active&#xD;
             cardiopulmonary resuscitation (CPR) during this hospitalization at treating&#xD;
             institution and/or referring institution;&#xD;
&#xD;
         18. Evidence of irreversible neurological compromise;&#xD;
&#xD;
         19. Life expectancy &lt; one (1) year;&#xD;
&#xD;
         20. Use of thrombolytics or glycoprotein IIb/IIIa inhibitor within 3 days prior to&#xD;
             inclusion in the study;&#xD;
&#xD;
         21. Use of non-vitamin K oral anti-coagulants (NOACs), such as rivaroxaban (Xarelto®),&#xD;
             apixaban (Eliquis®), dabigatran (Pradaxa®), edoxaban (Savaysa®) within 48 hours prior&#xD;
             to inclusion in the study;&#xD;
&#xD;
         22. Profound bradycardia requiring a temporary pacemaker and/or inotropic support;&#xD;
&#xD;
         23. Previous enrollment in this study;&#xD;
&#xD;
         24. Morbidly obese patient who by the judgement of the investigator is high risk for&#xD;
             bleeding;&#xD;
&#xD;
         25. BMI &gt; 45kg/m2;&#xD;
&#xD;
         26. Absolute contraindication to anticoagulation;&#xD;
&#xD;
         27. Uncontrolled hypertension defined as SBP &gt; 175mmHg and / or DBP &gt; 110mmHg with&#xD;
             pharmacotherapy within two (2) hours prior to inclusion in the study;&#xD;
&#xD;
         28. Currently participating in another study;&#xD;
&#xD;
         29. Any arterial line placement;&#xD;
&#xD;
         30. Current positive COVID diagnosis, or ≤ 8 weeks negative of COVID, or &gt; 8 weeks from&#xD;
             positive COVID test and with current symptoms, or current active viral pneumonia on&#xD;
             chest CT scan;&#xD;
&#xD;
         31. In the opinion of the investigator, the subject is not a suitable candidate for the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Firth, MD, PhD, MBA, FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thrombolex, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chris Schultz, BS</last_name>
    <phone>719-400-7463</phone>
    <email>cschultz@ecr-inc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammy Graham, RN, BSN, MBA, CCRP</last_name>
      <phone>310-794-9202</phone>
      <email>tfloore@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>John Moriarty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Cardiac &amp; Vascular Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenia Capdevilla, RN, CCRC</last_name>
      <phone>786-596-4068</phone>
      <email>keniac@baptisthealth.net</email>
    </contact>
    <investigator>
      <last_name>Ripal Gandhi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advent Health Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maggie Warrington, RN</last_name>
      <phone>407-303-9982</phone>
      <email>Maggie.Warrington@AdventHealth.com</email>
    </contact>
    <investigator>
      <last_name>Rohit Bhatheja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Fiebach</last_name>
      <phone>404-686-7468</phone>
      <email>afiebac@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Wissam Jaber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Heart Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Corley, BSN, BS</last_name>
      <phone>404-605-3118</phone>
      <email>Suzanne.Corley@piedmont.org</email>
    </contact>
    <investigator>
      <last_name>Charles Ross, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Klein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loyola University Chicago</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60521</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Del Priore, RN</last_name>
      <phone>708-216-2644</phone>
      <email>jdelpri@luc.edu</email>
    </contact>
    <investigator>
      <last_name>Amir Darki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ascension St. Vincent</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damian Horner, RN</last_name>
      <phone>317-338-9337</phone>
      <email>damian.horner@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Kannan Natarajan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ascension St. John Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Bess, BS, RDCS, RVT, CCRP</last_name>
      <phone>313-343-4811</phone>
      <email>renee.bess@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Antonious Attallah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital, Royal Oak</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Jeanne Balasote, RN</last_name>
      <email>SarahJeanne.Balasote@beaumont.org</email>
    </contact>
    <investigator>
      <last_name>Terry Bowers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Novitzke, RN BSN MPA</last_name>
      <phone>612-624-4865</phone>
      <email>novit001@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Rosenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New York</state>
        <zip>13088</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Mowers</last_name>
      <phone>315-234-4412</phone>
      <email>laura.mowers@sjhcardiology.org</email>
    </contact>
    <investigator>
      <last_name>Ayman Iskander, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Martirosyan, MPA</last_name>
      <phone>212-263-0414</phone>
      <email>Karen.Martirosyan@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Nancy Amoroso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NC Heart</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Pierre-Louis, MD</last_name>
      <phone>919-784-7695</phone>
      <email>James.Pierre-Louis@unchealth.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Mendes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Mt Carmel</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elissa Vankirk</last_name>
      <phone>614-546-4327</phone>
      <email>elissa.vankirk@mchs.com</email>
    </contact>
    <investigator>
      <last_name>Noah Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hamot</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16550</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patty Henry</last_name>
      <phone>814-877-3635</phone>
      <email>henrypc@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Maholic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gayle Jones, RN</last_name>
      <phone>215-707-1041</phone>
      <email>gayle.jones@tuhs.temple.edu</email>
    </contact>
    <investigator>
      <last_name>Parth Rali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Heart and Vascular Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Brimmeier, BSN, RN</last_name>
      <phone>412-623-8486</phone>
      <email>brimmeierja@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Rabih Chaer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennova Heart - Turkey Creek</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37934</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Polk, RN, CRCC</last_name>
      <phone>865-218-7535</phone>
      <email>beth.polk@tennova.com</email>
    </contact>
    <investigator>
      <last_name>Malcolm Foster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CAMC</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brianna Knapp, BBA, CRCC</last_name>
      <phone>304-388-9956</phone>
      <email>briana.knapp@camc.org</email>
    </contact>
    <investigator>
      <last_name>Aravinda Nanjundappa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 28, 2020</study_first_submitted>
  <study_first_submitted_qc>January 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2020</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Embolism</keyword>
  <keyword>Catheter Directed Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

